₹1,448.60
−0.82%NSE close, 16 Nov 2026
+58.31%
Alivus Life Sciences is a small cap company, listed on NSE under the symbol ALIVUS. At ₹1,448.60 a share, the market values the whole company at ₹17,785 crore.
In FY26, it reported sales of ₹2,552 crore and a net profit of ₹564 crore, an operating margin of 31.2%. Over the last three years, sales grew 5.7% a year and net profit grew 6.5% a year.
The market values the company at 26.6 times its profit over the last twelve months and 4.90 times its book value; its return on equity is 18.4% and it has almost no borrowings.
Promoters hold 74.85% of the shares. Foreign institutions hold 5.93%, and domestic institutions, mutual funds among them, 7.03%.
Over the past year the share price has risen 62.7%, and it is 6.8% below its 52-week high.
₹ crore. Standalone figures: the company files no consolidated results.
Update on acquisition
Disclosure under Regulation 30 of SEBI (LODR), 2015
Transcript
Schedule of meet
| Dec 2025 |
|---|
| Mar 2026 |
|---|
| Jun 2026 |
|---|
| Sep 2026 |
|---|
| Sales | 573 | 537 | 589 | 507 | 642 | 650 | 602 | 588 | 673 | 689 | 640 | 682 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Expenses | 400 | 395 | 429 | 373 | 452 | 451 | 430 | 409 | 442 | 475 | 429 | 417 |
| Operating profit | 173 | 141 | 159 | 134 | 190 | 198 | 172 | 179 | 231 | 215 | 212 | 265 |
| Operating margin | 30.1% | 26.4% | 27.1% | 26.5% | 29.7% | 30.5% | 28.6% | 30.5% | 34.4% | 31.1% | 33.1% | 38.9% |
| Other income | 1.7 | 3.1 | 5.5 | 8.5 | 10.5 | 10.1 | 9.0 | 14.7 | 13.9 | 22.8 | 22.4 | 19.9 |
| Interest | 0.4 | 0.4 | 0.4 | 0.3 | 0.5 | 1.3 | 1.3 | 1.3 | 1.5 | 1.3 | 1.3 | 1.3 |
| Depreciation | 13.2 | 14.5 | 14.4 | 15.1 | 15.2 | 16.0 | 17.1 | 18.4 | 19.7 | 20.2 | 20.6 | 21.8 |
| Profit before tax | 161 | 130 | 150 | 127 | 185 | 191 | 163 | 174 | 198 | 216 | 212 | 262 |
| Tax | 41.9 | 31.7 | 38.8 | 32.1 | 48.2 | 49.4 | 41.5 | 44.1 | 48.1 | 53.1 | 52.2 | 65.2 |
| Net profit | 119 | 97.9 | 111 | 95.3 | 137 | 142 | 122 | 130 | 150 | 163 | 160 | 197 |
| EPS (₹) | 9.69 | 7.99 | 9.10 | 7.78 | 11.18 | 11.57 | 9.91 | 10.60 | 12.25 | 13.23 | 13.04 | 16.02 |
₹ crore, financial years to March.
| Line | FY22 | FY23 | FY24 | FY25 | FY26 |
|---|---|---|---|---|---|
| Sales | 2,123 | 2,161 | 2,283 | 2,387 | 2,552 |
| Expenses | 1,507 | 1,519 | 1,609 | 1,704 | 1,755 |
| Operating profit | 616 | 642 | 674 | 683 | 797 |
| Operating margin | 29.0% | 29.7% | 29.5% | 28.6% | 31.2% |
| Other income | 14.7 | 29.0 | 12.0 | 34.6 | 60.4 |
| Interest | 28.0 | 0.6 | 1.6 | 2.4 | 5.4 |
| Depreciation | 37.9 | 42.1 | 53.5 | 60.6 | 75.4 |
| Profit before tax | 565 | 629 | 631 | 654 | 751 |
| Tax | 146 | 162 | 160 | 169 | 187 |
| Net profit | 419 | 467 | 471 | 486 | 564 |
| EPS (₹) | 35.63 | 38.10 | 38.42 | 39.63 | 45.99 |
₹ crore, at each year's end and the latest half year.
₹ crore, by financial year, and the latest half year.
| Line | FY22 | FY25 | FY26 | 6M to Sep 2026 |
|---|---|---|---|---|
| From operations | 598 | 392 | 565 | 460 |
| From investing | −122 | −616 | −570 | −371 |
| From financing | −78.8 | −6.2 | −64.3 | −65.4 |
| Spent on fixed assets | −132 | −166 | −307 | −190 |
| Free cash flow | 465 | 225 | 258 | 270 |
Margins, returns, debt, tax and cash.
| Line | FY22 | FY23 | FY24 | FY25 | FY26 |
|---|---|---|---|---|---|
| Net margin | 19.7% | 21.6% | 20.6% | 20.3% | 22.1% |
| Operating margin | 29.0% | 29.7% | 29.5% | 28.6% | 31.2% |
| Return on equity | – | 21.8% | 20.2% | 17.2% | 16.9% |
| Return on capital employed | – | 29.4% | 27.1% | 23.3% | 22.7% |
| Return on assets | – | 17.3% | 16.5% | 14.2% | 14.2% |
| Debt to equity | – | 0.00 | 0.00 | 0.00 | 0.00 |
| Interest coverage | 21.20 | 1,143.90 | 408.30 | 272.40 | 140.90 |
| Debt to assets | – | 0.00 | 0.00 | 0.00 | 0.00 |
| Current ratio | – | 3.67 | 4.37 | 4.97 | 5.21 |
| Quick ratio | – | 2.47 | 2.85 | 3.53 | 3.85 |
| Cash ratio | – | 0.56 | 0.69 | 0.15 | 0.00 |
| Asset turnover | – | 0.80 | 0.80 | 0.70 | 0.64 |
| Fixed asset turnover | – | 2.79 | 2.87 | 2.53 | 2.51 |
| Inventory turnover | – | – | 1.50 | 1.60 | 1.50 |
| Receivables turnover | – | 2.70 | 3.00 | 2.50 | 2.40 |
| Gross margin | – | – | 56.1% | 54.7% | 58.2% |
| Cash from operations to profit | 143.0% | – | – | 81.0% | 100.0% |
| Effective tax rate | 25.9% | 25.7% | 25.4% | 25.8% | 24.9% |
Schedule of meet.
Link of Recording of Earning Call.
Exercise of 195833 Options.
Press Release of the Company for the Second Quarter and Half Year ended September 30, 2026
The financial results for the period ended September 30, 2026.
Announcement under Regulation 30 of SEBI (LODR), 2015 - Acquisition.
The Company has incorporated a wholly owned subsidiary company in Brazil.
Proceedings of Annual General Meeting held on September 08, 2026. Further, the company has submitted the Exchange a copy of Scrutinizers report along with voting results.
Alivus Life Sciences announces acquisition of majority stake in IQGenX